Pbk drives parp inhibitor resistance through the trim37/nfκb axis in ovarian cancer

HIGHLIGHTS

• who: Hanlin Ma from the In vivo tumor xenograft animal model All experimental protocols were conducted within Shandong University guidelines for animal research and were approved by the Institutional Animal Care and Usecells stably infected with have published the research: PBK drives PARP inhibitor resistance through the TRIM37/NFu03baB axis in ovarian cancer, in the Journal: (JOURNAL) of 20/07/2022
• what: The authors demonstrated that PBK directly interacts with TRIM37 to promote its phosphorylation and nuclear translocation, which subsequently activates the NFu03baB pathway in ovarian cancer cells.
• how: These data indicated that . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.